Introduction

Pancreatic cancer is currently the fourth leading cause of cancer-related mortality. Less than 5% patients survive for 5 years after diagnosis with the median survival period of 4 to 6 months [1,2]. Although surgical resection is regarded as the most effective method of therapy, its feasibility remains low because of local advancement and early metastasis [3]. In addition, chemotherapy is considered as an important option in clinical therapy, but it usually produces poor effects [4,5]. Therefore, it is necessary to decipher the mechanisms underlying the high level chemoresistance of pancreatic cancer cells.

In recent years, cancer stem cells (or termed as tumor initiating cells) have been identified as an integral part in multi types of solid tumors [6–11]. Cancer stem cells not only result in tumor initiation and growth, but also act as the origin of chemoresistance in multi-types of solid tumors. Increasing evidences suggest that cancer stem cells reside in the cells capable of forming holoclones continuously. However, in pancreatic cancer, holoclone-forming cells have not been characterized yet. Therefore, the goal of our present study was to indentify the holoclone-forming pancreatic cancer stem cells and develop an in vitro continuous colony formation system, which will greatly facilitate the study of pancreatic cancer stem cells.

Methodology/Principal Findings: Pancreatic cancer cell line BxPC3 was submitted to monoclonal cultivation to generate colonies. Based on the morphologies, colonies were classified and analyzed for their capacities of secondary colony formation, long-term survival in vitro, tumor formation in vivo, and drug resistance. Flowcytometry and quantitative RT-PCR were performed to detect the expression level of cancer stem cells associated cell surface markers, regulatory genes and microRNAs in distinct types of colonies. Three types of colonies with distinct morphologies were identified and termed as holo-, mero-, and paraclones, in which only holoclones generated descendant colonies of all three types in further passages. Compared to mero- and paraclones, holoclones possessed higher capacities of long-term survival, tumor initiation, and chemoresistance. The preferential expression of cancer stem cells related marker (CXCR4), regulatory genes (BMI1, GLI1, and GLI2) and microRNAs (miR-214, miR-21, miR-221, miR-222 and miR-155) in holoclones were also highlighted.

Conclusions/Significance: Our results indicate that the pancreatic tumor-initiating cells with high level of chemoresistance were enriched in holoclones derived from BxPC3 cell line. Generation of holoclones can serve as a novel model for studying cancer stem cells, and attribute to developing new anti-cancer drugs.
related genes were highly expressed in holoclones derived from both prostate cancer and glioma cell lines [19,20]. These clues suggested that propagation of holoclones from cancer cell lines could serve as an alternative strategy for enrichment of cancer stem cells [20]. However, in pancreatic cancer, holoclones have not been identified and its correlation with properties of cancer stem cells has not been determined yet.

In the present study, we addressed the heterogeneity in pancreatic cancer cell lines BxPC3 [22] and PC3 [23] based on the morphology of colonies derived from single cancer cells and demonstrated that cancer stem cell properties were enriched in holoclones exclusively. Furthermore, our work indicated the holoclone forming cells attribute to chemoresistance, which indicated its potential value to develop chemotherapeutic drugs.

Results

Pancreatic cancer cells exhibit heterogeneous capacity to generate diverse colony morphologies in clonal culture

The first aim of our study was to determine whether the diversity of clonal morphologies exists in pancreatic cancer cell population, so monoclonal cultivation was carried out (Fig. 1A) with pancreatic cancer cell line BxPC3. This cell line was derived from primary loci of pancreatic adenocarcinoma and with typical epithelium morphology. After plated, a portion of cells died, while the others were kept viable and formed colonies within 3 days after plating and showed a spectrum of distinguishable morphologies after 5–7 days. Based on differences in morphology, colonies were defined as holoclones, meroclones and paraclones (Fig. 1B, C, D) [21]. Holoclones were clusters of homogeneous, small and tightly packed cells with regular and smooth colony borderlines (Fig. 1B). Paraclines consisted of dispersed and larger cells with fragmented borderlines (Fig. 1D). Meroclones exhibited intermediate morphologies (Fig. 1C). These morphologies were maintained when size of colonies increased. With parallel assays performed with PC3 cell line, three types of colonies were identified (Fig. S1A, B, C) with the morphologies similar to those derived from BxPC3 cell line. The colony composition was similar in these two cell lines: nearly half of the colonies were meroclines, whereas holoclones and paraclones accounted for about 20–30% of the colonies formed (Fig. 1E, Fig. S1D). Therefore, these data indicated the diversity of clonal morphologies in pancreatic cancer cell population.

Different types of colonies possess differential capacities for self-renewal and long-term proliferation

Since the clonal morphological diversity in pancreatic cancer cells had been indicated, the secondary colony formation capacity should be assessed. For this purpose, cells from all three types of colonies were isolated and replated with low density (less than 200 cells per well of 6-well plate) for several passages. At initial passage, the holoclones generated similar proportions of secondary holoclones and meroclines (nearly 50% each), with limited number (less than 10%) of paraclones (Fig. 2A, Fig. S2A). In parallel assays, cells isolated from meroclones produced a rare number of secondary holoclones but a much higher percentage of paraclones (Fig. 2C, Fig. S2C). However, rare cells of paraclones were kept viable after re-plating and generated only secondary paraclones at low frequency (data not shown). To follow the developmental fate of colonies, typical colonies of distinct type were selected for long-term culture. Cells in selected colonies were passaged routinely at clonal density under common condition. For colonies derived from BxPC3 cell line, all 12 holoclones were viable and proliferated robustly, whereas 12 of 18 meroclines and 13 of 15 paraclones were gradually aborted (Fig. 3) during parallel culture of 140 days. Similarly, during 60 days’ passage of colonies derived from PC3 cell line, 8 of 9 holoclones were in robust expansion while 4 of 8 meroclines and 6 of 8 paraclones declined in short period (Fig. S3).

Figure 1. Colony heterogeneity in pancreatic cancer cell line BxPC3. (A) Schematic depicting the procedure of deriving BxPC3 cell clonal cultures and functional assays. Lower panels show representative holoclones (B), meroclones (C) and paraclones (D) from BxPC3 cultures. All photographs were taken at 2 weeks after plating (Bar, 100 microns). At this time point, each type of colonies was counted (E). The results from repeated experiments (n = 4) are presented as means ± s.e.m in histogram. doi:10.1371/journal.pone.0023383.g001

Figure 2. Self-renewal capacity of distinct types of colonies. Cells isolated from single colonies were plated at low density under common condition. (A) At the initial passage, holoclones (n = 8) mainly produced similar frequencies of descendant holoclones and meroclines, whereas much lower percentages of paraclones were generated. (B) After passages of one more month, holoclones (n = 8) generated the full range of progeny colonies at frequencies similar to those retained in unsorted parental cell lines. (C) Meroclones (n = 8) mainly produced paraclones and meroclines, and few holoclones were generated. doi:10.1371/journal.pone.0023383.g002
Interestingly, only cells derived from holoclones regenerated the full range of colon morphologic phenotypes and restored the proportions of each type of colonies (Fig. 2B, Fig. S2B) similar to the proportions observed in unsorted parental cell lines under low density culture. Based on the distinct appearance exhibited above, the capacity of long-term self-renewal in vitro mainly resided in holoclones, but not meroclones or paraclones.

Holoclones, but not meroclones or paraclones, initiate tumor formation and support tumor serial transplantation in NOD/SCID mice. For the robustness of holoclones had been shown in vitro, it was important to evaluate the in vivo tumorigenecity of three types of colonies. In order to estimate the tumor formation capacity of each type of colony, serial transplantation assays were performed. Firstly, unsorted BxPC3 cells initiated tumor formation in a dose dependent manner. 100% of mice injected with 10^6 or 10^5 BxPC3 cells developed xenograft tumors after 14 days, and mice injected with 10^4 or 10^3 cells also developed xenograft tumors after 21 days with 100% efficiency (Table 1). After that, three holoclones, three meroclones, and two paraclones were picked out for transplantation. 10^4 holoclone cells formed palpable tumors in 100% of mice (15 of 15 mice) within 18 days. On the contrary, no visible tumors were formed by cells from mero- or paraclones (0 of 36 mice, 10^4~10^3 cells per mouse) within 2 months (Table 1). In a further step, cells in xenograft tumors derived from holoclones were then purified and re-transplanted to NOD/SCID mice (10^4 cells per mouse). Within 18 days, all recipient mice (18 of 18 mice) developed palpable tumors (Table 1). Serial transplantation assays were also performed on PC3 cell line. Unsorted parental cell line, 3 holoclones, 2 meroclones, and 2 paraclones were employed. All the holoclones derived from PC3 cell line were able to develop tumor exclusively in short latency (Table S3).

Exnograft tumors derived from unsorted BxPC3 cell line and corresponding holoclones were analyzed with H&E staining. The histological characteristics of xenograft tumor specimens was visualized and showed high level of similarity between tumor samples from unsorted cell line (Fig. S4A, B) and corresponding holoclones (Fig. S4C, D).

With the significant difference of tumor formation capacity among distict types of colonies, it was suggested that the tumor-initiation capacity in vivo was enriched in holoclones rather than meroclones or paraclones.

Cancer stem cells related surface markers, genes and microRNAs are differentially expressed in distinct types of colonies. Based on the characteristics of holoclones in vitro and in vivo, it was necessary to analysis the expression of cell-surface markers...
and regulators associated with cancer stem cells in three types of colonies. Therefore, flow-cytometry and quantitative RT-PCR were employed simultaneously. Flow-cytometric assays showed that CD133 was negative (Fig. 4A) and CD44 was positive (Fig. 4C) in holoclones, meroclones and paraclones. All types of colonies contained both CXCR4+ and CXCR4− cells, however, the percents of CXCR4+ cells were much higher in holoclones than in meroclonies and paraclonies (Fig. 4B). The CD24 intensity (Fig. 4D, Fig. S5) was significantly stronger in paraclonies than in holoclones. Similar results were obtained with quantitative RT-PCR. CD133 was not detectable and CD44 showed less than 1.3-fold of up-regulation in holoclones than in paraclonies (Fig. 4E). However, expression of CD24 in holoclones was down-regulated for about 5-fold than in paraclonies (Fig. 4F). Expression level of CXCR4 was about 3-fold higher in holoclones than in paraclonies (Fig. 4G). Furthermore, Expression of BMI-1, GLI1, GLI2, GLI3 and a list of cancer related microRNAs were also quantified. BMI-1, GLI1 and GLI2 were up-regulated in holoclones rather than in paraclonies, while expression level of GLI3 was not significantly changed among three types of colonies (Fig. 5A). MicroRNAs were showed differentially expressed and clustered into two groups: one group was up-regulated in holoclones, including miR-214, miR-21, miR-221, miR-222, and miR-155 (Fig. 5B); the other group was down-regulated in holoclones, including Let-7a and miR-30c, miR-30h, miR-30a (Fig. 5C). The differential expression of markers and regulators also suggest the tendency that stem cell properties were possessed by holoclones rather than other two types of colonies.

**Holoclones exhibit much higher chemoresistance than meroclones and paraclonies**

It’s well known that chemoresistance is one of the major properties of cancer stem cells, so here we asked whether the holoclones possess this ability. Hence, the cells isolated from these three types of colonies and treated with gemcitabine and 5-FU under increasing concentration. Among the entire concentration range tested, the survival rates of cells derived from holoclones were significantly higher than those from meroclonies and paraclonies (Fig. 6A, B). The IC_{50} value of 5-FU was 2.59×10^{5} nM in holoclones, which was much higher than those of meroclonies (1.24×10^{5} nM) and paraclonies (15.10 nM). To analyze the gene expression change induced by drug treatment, quantitative RT-PCR was carried out with the cells treated with drugs. After treatment with 50 nM of 5-FU for 12 hours, expression of the drug-intake transporters (SLC28A1, SLC28A2, SLC29A3, SLC29A1, SLC29A2, SLC29A3) were all up-regulated in paraclonies with no effect in holoclones mostly (only SLC29A1 was down-regulated about 2-fold) (Fig. 6C).With the parallel treatment of gemcitabine, similar responses of these genes were detected (Fig. 6C). Taken together, SLC28A1/A2 and SLC29A1/A3 were commonly up-regulated more dramatically in paraclonies than in holoclones after treatments of gemcitabine or 5-FU. This differential response might be, at least partly, involved in the variation of chemoresistance among three types of colonies.

**Discussion**

In present study, we demonstrated the stem cell properties of holoclones and indicated that a panel of stem cell associated genes and microRNAs were preferentially expressed in holoclones. Moreover, we revealed a high level chemoresistance in holoclones and suggested the potential value of holoclones in study of cancer stem cells.

We are the first to show the heterogeneity in clonal morphologies of pancreatic cancer cells. Similar to the behavior of keratinocyte [21] and multiple cancer cell lines [18–20], when cells of BxPC3 and PC3 cell line were plated monolocnally, a serial of colonies with diverse morphologies were developed (Fig. 1A). Based on the morphological diversity, holoclones (Fig. 1B, Fig. S1A), meroclones (Fig. 1C, Fig. S1B) and paraclonies (Fig. 1D, Fig. S1C) can be easily identified.

Furthermore, our results indicated that stem-like cancer cells were enriched in holoclones rather than mero- or paraclonies. During *in vitro* propagation, cells in holoclones generated a high percentage of progeny holoclones at the first round of passage (Fig. 2A, Fig. S2A). After more passages, cells in holoclones generated colonies with full range of morphological characteristics similar to that derived from unsorted parental cell lines (Fig. 2B, Fig. S2B). However, meroclones generate a limited level of holoclones and much higher percentages of paraclonies (Fig. 2C, Fig. S2C). During long-term of passages *in vitro*, holoclones showed more robustness and constant proliferation, while mero- and paraclonies declined rapidly (Fig. 3, Fig. S3). With the differences shown above, distinct types of colonies possessed differential capacity of self-renewal and proliferation capacity. More importantly, holoclones serially initiated tumor development *in vitro* while mero- and paraclonies did not (Table 1, Table S3), which is regarded as the widely used golden standard for identification of cancer stem cells. As an indispensable supplement, the xenograft tumors derived from BxPC3 holoclones showed similar histological characteristics with those tumor tissue derived from unsorted BxPC3 cell line (Fig. S4). In prostate cancer cells lines PC3 [19] and DU145 [24], similar characteristics of holoclones *in vitro* and *in vivo* had been indicated and served as evidences to support the stem cell property of holoclones.

Moreover, expression of cell surface markers, genes and microRNAs among distinct types of colonies also suggested the stem cell property of holoclones. Firstly, the cell surface markers of pancreatic cancer stem cells, CD44, CD24, and CD133, were identified as population of CD44+, CD24+, and CD133+ cells were much higher in holoclones than in meroclonies and paraclonies (Fig. 2C, Fig. S2C). During long-term of passages *in vitro*, holoclones showed more robustness and constant proliferation, while mero- and paraclonies declined rapidly (Fig. 3, Fig. S3). With the differences shown above, distinct types of colonies possessed differential capacity of self-renewal and proliferation capacity. More importantly, holoclones serially initiated tumor development *in vitro* while mero- and paraclonies did not (Table 1, Table S3), which is regarded as the widely used golden standard for identification of cancer stem cells. As an indispensable supplement, the xenograft tumors derived from BxPC3 holoclones showed similar histological characteristics with those tumor tissue derived from unsorted BxPC3 cell line (Fig. S4). In prostate cancer cells lines PC3 [19] and DU145 [24], similar characteristics of holoclones *in vitro* and *in vivo* had been indicated and served as evidences to support the stem cell property of holoclones.
Holoclones Enrich Pancreatic Cancer Stem Cells

A
Isotype Control  Holoclones  Meroclines  Paraclones

B
counts
CD133
0.15%  16.2%  3.05%  3.02%

C
counts
CXCR4

D
counts
CD44

E
counts
CD24

F
Expression Level
holo  mero  para

G
Expression Level
holo  mero  para

*
expression in CD44⁺CD24⁻ESA⁺ cancer stem cells isolated from human primary pancreatic cancer specimens [20]. The Hedgehog signal pathway also plays an essential role in maintaining cancer stem cells in mammary [31] and brain [36]. CXCR4, the pivotal mediator of metastasis, was up-regulated in holoclones (Fig. 4B, G) too. In CD133⁺ pancreatic cancer stem cells, the CXCR4⁺ subpopulation is more invasive than autologous CXCR4⁻ subpopulation [11]. Among microRNAs up-regulated in holoclones, miR-214, miR-221, miR-222 and mir-155 (Fig. 5B) were commonly overexpressed in breast cancer stem cells [37]. However, Let-7a (Fig. 5C), which was significantly down-regulated in holoclones, plays a negative role in self-renewal, tumorigenicity, and chemoresistance of breast cancer stem cells [12]. Similarly, miR-30a/b/c (Fig. 5C) were also overexpressed in paraclines. In breast cancer, this microRNA family inhibits self-renewal of stem cells, induces apoptosis, and reduces the metastasis to lung [30].

Higher level of chemoresistance was indicated in holoclones rather than in meroclones and paraclines (Fig. 6A, B), which is consistent with the supportive role of cancer stem cells in chemoresistance reported previously [11,13]. In accordance with the robust chemoresistance in holoclones, genes and microRNAs that sustain chemoresistance, including BMI1 [39], GLI1/2 [40], CXCR4 [41], miR-214 [42], miR-21 [43], and mir-155 [44] (Fig. 4G, Fig. 5A, B) were up-regulated in holoclones. In response to drug treatments, the expression of drug-intake transporters, of which the higher expression level was correlated with longer survival of patients [45–48], was induced in paraclines preferentially (Fig. 6C). This means the drug in-take will be increased more rapidly in paraclines than in holoclones. This could be one of the potential origins of preferential survival of cancer stem cells versus non-stem cancer cells in chemotherapy.

Taken together, the colonies with distinct morphologies and in different stages of differentiation can serve as a potential model for analysis of cancer stem cells (Fig. 7). With this model, genes and microRNAs potentially correlated with cancer stem cells can be identified. More importantly, parallel evaluation of chemotherapeutic drugs can be carried out on cancer stem cells and autologous non-stem cancer cells. This means the clonal morphologies based cancer stem cell model will be useful to lead to the newer understanding of chemoresistance, which should be quite different from those obtained from heterogeneous cancer cell populations, and will be helpful to overcome the chemoresistance in cancer therapy.

Materials and Methods

Cell lines

Human pancreatic adenocarcinoma cell line BxPC3 (purchased from Cell Bank of China Academy of Sciences, Shanghai, China) and PC3 were (purchased from China Union Medical Collage, Beijing, China) cultured in RPMI-1640 (Hyclone) with 10% heat inactivated fetal bovine serum (Hyclone) and passaged as 1:10 with 0.25% trypsin/EDTA (Hyclone). These cell line were established from primary pancreatic ductal adenocarcinoma and with typical epithelium morphology [22,23]. BxPC3 [22] was derived from European descent and PC3 [23] was derived from Chinese.

Chemical drugs

Lyophilized powder of gemcitabine (Lilly) was dissolved in Calcium/Magnesium free PBS (Hyclone) and stored at −20°C with concentration of 4 mg/ml. 5-FU solution (Roche) was stored at −20°C with concentration of 25 mg/ml. Before use, stocks were diluted to working concentrations (5, 10, 50, 100, and 500 nM for 5-FU, and 1, 5, 10, 50, and 100 nM for Gemcitabine) with culture medium.

Animals

All experiments were approved by the Animal Care and Use Committee of Peking University (approval number was IRR0001052-09051). NOD/SCID mice were purchased from Experimental Animal Sciences Center of Peking University and maintained in standard condition according to the institutional guidelines.

Single cell cloning

Cells were harvested at 70%–80% of confluence with Accumax (Chemicon) and resuspended in medium without serum.
cell was seeded into each well of 96-well plates with MOFLO flow cytometry (DakoCytomation). Two days after plating, 96-well plates were checked with microscopy. Wells containing only one viable cell were marked. And then, medium was refreshed every 3 days. Colonies were classified as holo-, mero-, and paraclones according to their morphologies. 14 days after flow-cytometric sorting, typical colonies were selected for further experiments.

**Tumor cell implantation**
Selected colonies were expanded and harvested with Accumax (Chemicon), counted and resuspended in 1:1 mixture of RPMI-1640 and Matrigel (BD). Aliquots of cell suspension were injected subcutaneously into dorsolateral part of NOD/SCID mice. Tumor latency (i.e., time from injection to detection of palpable tumors) was determined. Within 9 weeks after implantation, tumor-bearing mice were sacrificed. Meanwhile, xenograft tumors were dissected out surgically and weighed. Mice with no sign of tumor burden were kept for at least 9 weeks since implantation and then examined on necroscopy to confirm that they were tumor-free.

For serial transplantation, xenograft tumors were minced into small pieces with scissors, suspended in M199 medium, and digested at 37°C for about 3 hours with 200 units/ml ultrapure collagenase IV (Worthington Biochemicals). Further mechanical digestion was performed with a 23-ml pipette every 15 minutes. After digestion, cell suspension was filtered through a 40-μm nylon mesh and gently loaded onto the top layer of Histopaque-1077 gradient (Sigma-Aldrich) (1–3×10^6 cells/ml histopaque used in total volume of 3 mL) and then centrifuged at 400 g for 30 minutes at room temperature. Viable nucleated cells were collected at the interface, while red blood cells, dead cells and debris were eliminated. The harvested single-cell suspension was used for transplantation as described above.

**Chemoresistant assay**
Cells from the same type of colonies were harvested, pooled together and seeded into 96-well plates with density of 5000 cells/well. 24 hours later, medium was refreshed and drugs (gemcitabine or 5-FU) were added. After 72 hours of drug treatment, 10% volume of WST-8 reagent (Beyotime) was added into all wells and plates were incubated at 37°C for 1 hour. The absorbance at 450 nm wavelength was measured with plate-reader (Bio-Rad). Based on the survival rate under different drug concentration, IC_{50} were calculated.

**Flowcytometric assay**
Cells harvested from pooled colonies of the same type were resuspended in HBSS containing 2% FBS at concentration of 10^6 cells/ml. Antibodies were then added into the sample aliquots. After 30 minutes incubation on ice, the samples were washed.
twice with HBSS with 2% FBS and analyzed with FACSCalibur (BD). Following antibodies were used: PE-Cy5 conjugated anti-human/mouse CD44 (eBioscience), PE conjugated anti-human CD24 (eBioscience), PE conjugated anti-human CD133 (miltenyibiotec) and APC conjugated anti-human CXCR4 (eBioscience). Pulse width and side scatter profiles were used to eliminate cell doublets, dead cells and cell debris.

Quantitative RT-PCR

Total RNA (including microRNA) was extracted from the cells with miRNeasy Kit (Qiagen) according to the user manual. Reverse transcription reactions for both mRNAs and microRNAs were carried out with miScript Reverse Transcription Kit (Qiagen).

Quantitative PCR assays for mRNAs were performed with SYBR Green PCR Master Mix (QPK-201) (TOYOBO). The PCR reactions were performed with following condition: 2 min at 95°C, followed by 35 rounds of 15 sec at 95°C and 1 min at 60°C. The relative expression of each gene was normalized against GAPDH. Primers used were shown in Table S1.

Quantitative PCR assays for microRNAs were performed with the miScript SYBR® Green PCR Kit (Qiagen). The PCR reactions were performed with following condition: 15 min at 95°C, followed by 35 rounds of 15 sec at 95°C and 30 sec at 55°C and 30 sec at 72°C. The relative expression of each microRNA was normalized against RNU-6b. Primers were all purchased from Qiagen. Their codes and catalog numbers were shown in Table S2.

All assays were performed with ABI PRISM 7300 Sequence Detection System and under the control of ABI 7300 SDS Software version 1.3.1.

H&E staining

Tissue samples were dissected from mice and fixed in 10% phosphate buffered formalin. After fixed, tissues were embedded in paraffin. According to standard histopathologic procedures, sections were cut 4-Am thick, mounted on poly-L-lysine coated slides, dried overnight at 37°C, dewaxed in xylene, rehydrated and stained with H&E.

Supporting Information

Figure S1 Colony heterogeneity in pancreatic cancer cell line PC3. Panels show representative holoclones (A), meroclones (B) and paraclones (C) from PC3 cultures. All photographs were taken at 2 weeks after plating (Bar, 100 microns). At this time point, each type of colonies was counted (D). The results from repeated experiments (n = 4) are presented as means ± s.e.m in histogram. (TIF)

Figure S2 Self-renewal capacity of distinct types of colonies derived from PC3 cell line. Cells isolated from single colonies were plated at low density under common condition. (A) At the initial passage, holoclones (n = 9) mainly produced similar frequencies of descendant holoclones and meroclones, whereas much lower percentages of paraclones were generated. (B) After passages of one month, holoclones (n = 8) generated the full range of progeny colonies with the frequencies similar to those retained in unsorted parental PC3 cell line. (C) Meroclones (n = 8) mainly produced similar amount of paraclones
and meroclines, and rare holoclones were generated simultaneously.

(TIF)

**Figure S3** Long-term propagation capacity of distinct types of colonies derived from PC3 cell line. Holoclones (n = 9, red line), meroclines (n = 8, green line) and paraclones (n = 8, blue line) were passage under common condition for 2 months. Life spans of each colony were recorded. 4 of 8 meroclines and 6 of 8 paraclones were aborted gradually, whereas 8 of 9 holoclones remained viable (p < 0.01).

(TIF)

**Figure S4** Histogramical characteristics of xenograft tumors derived from unsorted BxPC3 cell line and holoclones. 10^4 cells from unsorted cell line and holoclones were employed to produce xenograft tumors. H&E staining was performed to analyze the histological features of xenograft tumors derived from unsorted BxPC3 cell line (A) and holoclones (C) (Bar, 400 microns). The selected areas (black box) in panel A and C were magnified as panel B and D respectively (Bar, 100 microns).

(TIF)

**Figure S5** Expression of cancer stem cell markers CD44 and CD24 in holoclones and paraclones derived from pancreatic cancer cell line PC3. Cells in holoclones and paraclones derived from PC3 cell line were examined with flowcytometry for the cell surface markers of cancer stem cells. Flowcytometric plots (A) showed that CD44 (truminn axis) was strongly positive and with little difference among distinct types of colonies. Three gates were set up to show the high (R1), medium (R2) and low (R3) level of CD24 (vertical axis) expression. Representative plots showed that cells isolated from paraclones (right panel) tended to be distributed in gate R1 while cells isolated from holoclones (left panel) were dominantly distributed in gate R3. The distribution of cells in three gates was summarized (B) as below (p < 0.05).

(TIF)

**Table S1** Primers for real-time PCR of genes.

**Table S2** Primers for real-time PCR of microRNAs.

**Table S3** Tumorigence of distinct types of colonies derived from PC3 cell line.

**Acknowledgments**

We thank Ms. Liying Du (Life Sciences College, Peking University, Beijing, China) for the technical support in flow cytometry and Mr. Yizhe Zhang (Life Sciences College, Peking University, Beijing, China) for the technical support in real-time PCR. We also thank Dr. Chengyan Wang and Dr. Dongxin Zhao (Life Sciences College, Peking University, Beijing, China) for their suggestions in preparation of manuscript. Moreover, we need to show our gratitude to Mr. Ted Richard (Moffitt Cancer Center, Tampa, Florida, USA) for his help in improving English writing.

**Author Contributions**

Conceived and designed the experiments: LT MXD. Performed the experiments: LT XS. Analyzed the data: LT MXD. Contributed reagents/materials/analysis tools: HKD MXD. Wrote the paper: LT HKD MXD.

---

**References**

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al. (2004) Cancer statistics. CA Cancer J Clin 54: 8–29.

2. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, et al. (1996) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78: 627–632.

3. de Braud F, Cascini L, Gatta G (2004) Cancer of pancreas. Crit Rev Oncol Hematol 50: 147–155.

4. Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer 78: 634–663.

5. Rosenberg L (1997) Treatment of pancreatic cancer. Promises and problems of tumourin, somatostatin analogs, and gemcitabine. Int J Pancreat 22: 81–93.

6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3987–3992.

7. Singh SK, Hawkins C, Clarke J, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396–401.

8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10996–10991.

9. O’Brien GA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106–110.

10. Li C, Hecht DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030–1037.

11. Hermann PC, Huber SL, Herrer T, Aicher A, Elbert JW, et al. (2007) Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell 1: 313–323.

12. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Gloma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760.

13. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.

14. Shridaran C, Kishimoto H, Fuchs RK, Mehrotra S, Bharti-Nakshatri P, et al. (2006) CD44v6/CD24- breast cancer cells exhibit enhanced invasive properties, an early step necessary for metastasis. Breast Cancer Res 8: R59.

15. Kocht A, Kobayashi K, Barrandon Y (1994) Location of stem cells of human hair follicles by clonal analysis. Cell 76: 1063–1073.

16. Pellegrini G, Golsano O, Paterna P, Lambiase A, Bonini S, et al. (1999) Location and clonal analysis of stem cells and their differentiated progeny in the human ocular surface. J Cell Biol 145: 769–782.

17. Papini S, Cecchetti D, Campani D, Fitzgerald W, Grivel JC, et al. (2003) Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture. Stem Cells 21: 481–494.

18. Locke M, Heywood M, Fawell S, Mackenzie IC (2005) Retention of Intrinsic Stem Cell Hierarchies in Carcinoma-Derived Cell Lines. Cancer Res 65: 8944–8950.

19. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG (2008) PC3 Human Prostate Carcinoma Cell Holoclones Contain Self-Renewing Tumor-Initiating Cells. Cancer Res 68: 1820–1825.

20. Zhou ZH, Ping YF, Yu SC, Yi L, Yao XH, et al. (2009) A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett 281: 92–99.

21. Barrandon Y, Green H (1987) Three clonal types of keratinocyte with different capacities for multiplication. Proc Nat Acad Sci U S A 84: 2302–2306.

22. Tan MH, Nowak NJ, Loer R, Ochi H, Sandberg AA, et al. (1996) Characterization of a new primary human pancreatic tumor line. Cancer Invest 4: 15–23.

23. Quanci C, Jie C, Changjiang G, Dechun L, Tonghua L (1992) Establishment and Characterization of a New Human Pancreatic Adenocarcinoma Cell Line. Cancer Research 1992 52: 50–52.

24. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, et al. (2007) Prostate cancer stem/progenitor cells: identification, characterization, and Implications. Mol Carcinog 46: 1–14.

25. Dembinski JL, Krausz S (2009) Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 26: 611–623.

26. Silva IA, Bai S, McLean K, Yang K, Griffith KA, et al. (2011) Aldehyde dehydrogenase and CD133 define angiogenic ovarian cancer stem cells that predict poor patient survival. Cancer Res Epub ahead of print.

27. Guo R, Wu L, Liu F, Wang Y (2011) Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep 25: 141–14.

28. Ma L, Lai D, Liu T, Cheng W, Guo L (2010) Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai) 42: 593–602.

29. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, et al. (2010) Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep 25: 141–14.

30. Papini S, Cecchetti D, Campani D, Fitzgerald W, Grivel JC, et al. (2003) Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture. Stem Cells 21: 481–494.
31. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, et al. (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063–6071.

32. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, et al. (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302–305.

33. Rizo A, Olthof S, Han L, Vellenga E, de Haan G, et al. (2009) Repression of BMI1 in normal and leukemic human CD34+ cells impairs self-renewal and induces apoptosis. Blood 114: 1496–1505.

34. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, et al. (2009) BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 29: 8894–8896.

35. Hosen N, Yamane T, Muijtjens M, Pham K, Clarke MF, et al. (2007) Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells. Stem Cells 25: 1633–1644.

36. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A (2007) HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17: 165–172.

37. Shimono Y, Zabala M, Cho RW, Lobo N, Dalterba P, et al. (2009) Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells. Cell 138: 592–603.

38. Yu F, Deng H, Yao H, Lai Q, Su F, et al. (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29: 4194–4204.

39. Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Dunesi R, et al. (2010) BMI1 silencing enhances doxorubicin activity and impairs antioxidant response in prostate cancer. Int J Cancer: DOI 10.1002/ijc.25522.

40. Feldmann G, Dhara S, Hendrich V, Bedja D, Beatty R, et al. (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67: 2187–2196.

41. Singh S, Srivastava SK, Bhardwaj A, Owen PB, Singh AP (2010) CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 103: 1671–1679.

42. Yang H, Kong W, He L, Zhao J, O’Donnell JD, et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 423–433.

43. Park JK, Lee EJ, Esau C, Schmittgen TD (2009) Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Senses the Effects of Gemcitabine in Pancreatic Adenocarcinoma. Pancreas 38: e190–199.

44. Kong W, He L, Coppola M, Guo J, Kopito NN, et al. (2010) MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285: 17869–17879.

45. Kannu S, Huura T, Ohtake T, Konwai K, Suzuki H, et al. (2007) Characterization of resistance to cytostatic arabinoside (Ara-C) in NALM-6 human B leukemia cells. Clin Chim Acta 377: 144–149.

46. Molina-Arcas M, Marcé S, Villamor N, Huber-Ruano I, Casado EJ, et al. (2005) Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19: 64–68.

47. Marechéal R, Mackey JR, Lai R, Demetter P, Peeters M, et al. (2005) Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15: 2913–2919.

48. García-Manteiga J, Molina-Arcas M, Casado EJ, Mazo A, Pastor-Anglada M (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2’-2’-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9: 5000–5008.